Phase ii clinical trial of Ixabepilone in metastatic cervical carcinoma

Keyphrases

• Bowel Fistula 16%
• Cervical Carcinoma 100%
• Cisplatin 16%
• Drug Sensitivity 16%
• First Cycle 16%
• Glu-tubulin 16%
• Growth Rate 16%
• Ixabepilone 100%
• Later-line 16%
• Median Overall Survival 16%
• Median Progression-free Survival 16%
• Metastatic Breast Cancer 16%
• Microtubule Stability 33%
• Microtubule-stabilizing Agents 16%
• Nave 16%
• Naïve Patients 16%
• Overall Safety 16%
• Overall Survival 16%
• Partial Response 16%
• Phase II Clinical Trial 100%
• Poor Prognosis 16%
• Preclinical Data 16%
• Pretreated Patients 33%
• Previously Treated 16%
• Progression-free Survival 16%
• Resistant Cells 16%
• Response Evaluation Criteria in Solid Tumors (RECIST) 16%
• Response Rate 16%
• Response to Therapy 16%
• Second-line Therapy 16%
• Sensory Neuropathy 16%
• Squamous Histology 16%
• Target Engagement 50%
• Taxanes 83%
• Tubulin 16%
• Tubulin Acetylation 33%
• Tumor 33%
• Tumor Growth 16%
• Tumor Samples 16%
• Vomiting 16%
• Western Blot 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Taxane 83%